Yazar "Hatemi, G." seçeneğine göre listele
Listeleniyor 1 - 4 / 4
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Acknowledged statistical help and a better use of p-values: a proposal(Clinical & Exper Rheumatology, 2019) Dincses, E.; Guzelant, G.; Hatemi, G.; Sut, N.; Yazici, H.Objective. The p-value is commonly misused. We hypothesised that a close cooperation with a statistician would go along with a more proper use of p-values. We considered a close cooperation present, when a statistician was a coauthor, or a formal statistical help was acknowledged in a study report. Methods. Randomised controlled trials published in 2015-16 in 4 widely read rheumatology journals were searched for a close cooperation with a statistician, the inclusion of effect sizes, confidence intervals, exact rather than relative p-values and the omission of p-values in tables depicting trial entry data. Results. There were only 28/133 (21%) articles in which a formal statistical help was acknowledged (Group I). The rest (Group II) gave no acknowledgement of a close cooperation. Reporting of effect sizes (96% vs. 71%) and exact p-values (88% vs. 69%) were more in Group I (p=0.01, and p=0.08, respectively). Conclusion. While a formal acknowledgement of a close cooperation was notably infrequent at 21%, this went along with improvement in some aspects of p-value reporting. If substantiated by further studies, we propose that a formally acknowledged statistical help should improve p-value reporting. Like all professionals, statisticians would like their name/office to be formally associated with their good work.Öğe Frequent oral ulceration during early disease may predict a severe disease course in males with Behcet's syndrome(Clinical & Exper Rheumatology, 2012) Hamuryudan, V.; Hatemi, G.; Sut, N.; Ugurlu, S.; Yurdakul, S.; Yazici, H.Objective. The numbers and recurrence rates of mucocutaneous manifestations can be highly variable among patients with Behcet's syndrome (BS) but it is not known whether these differences influence the disease course at the long-term. Methods. We evaluated the outcome of 30 patients that made up the placebo arm of a 6 months controlled trial of thalidomide and looked at the relation between the frequencies of mucocutaneous manifestations during the trial and the development of major organ involvement necessitating immunosuppressives during the post-trial period. Results. Fifteen (50%) patients had received immunosuppresives for major organ involvement during the post-trial period. Patients receiving immunosuppressive treatment were significantly younger at the onset of BS compared to those who did not (24.5 +/- 5 vs. 29.7 +/- 3.8 SD years; p=0.003). The mean number of oral ulcers recorded throughout the trial was significantly higher among patients using immunosuppressives compared to those who did not (2.09 +/- 0.96 vs. 1.43 +/- 0.8; p=0.029). This significance disappeared when adjusted for age of onset of BS (p=0.16). ROC curve analysis showed that having 10 or more ulcers during 6 months has a sensitivity of 86.7% and a specificity of 53% for the subsequent necessity of immunosuppressive use. The same association was not true for genital ulcers, follicular lesions and erythema nodosum. Conclusion. These findings on a limited number of patients suggest that frequent occurrence of oral ulceration during the initial years of the disease may predict the development of major organ involvement in men with BS.Öğe Purified protein derivative reaction is not augmented in Behcets syndrome patients(Oxford Univ Press, 2008) Hatemi, G.; Melikoglu, M.; Sut, N.; Yazici, H.[Abstract Not Available]Öğe TNF-alpha antagonists and thalidomide for the management of gastrointestinal Behcet's syndrome refractory to the conventional treatment modalities: a case series and review of the literature(Clinical & Exper Rheumatology, 2015) Hatemi, I.; Hatemi, G.; Pamuk, O. N.; Erzin, Y.; Celik, A. F.Objective. Gastrointestinal involvement of Behcet's syndrome is usually treated with glucocorticoids, 5-aminosalicylic acid compounds and azathioprine. However, some patients are refractory to these conventional therapy modalities. In this paper we report our experience on 13 patients with gastrointestinal involvement of Behcet's syndrome who were refractory to the conventional therapy and who were treated with TNFalpha antagonists and/or thalidomide. Methods. We reviewed the charts of our Behcet's syndrome patients with gastrointestinal involvement and identified those who were treated with TNF alpha antagonists and/or thalidomide. Demographic features, previous and concomitant drugs, previous surgery, time to remission and duration of remission were tabulated. We also performed a systematic review of publications on gastrointestinal involvement of Behcet's syndrome patients treated with TNFalpha antagonists and/or thalidomide. Results. Among our 64 patients with gastrointestinal involvement of Behcet's syndrome, we identified 13 (20%) (7 women, 6 men, mean age 27.4 +/- 9.4) who had been treated with TNF-alpha antagonists and/or thalidomide. Their previous medications were glucocorticoids (13113), azathioprine (13113), 5-aminosalicylic acid derivatives (3113) and budesonide (1113). Clinical and endoscopic remission was obtained in 10 patients. One patient died with sepsis. The systematic literature search revealed 91 cases who had used TNFalpha antagonists and 15 who had used thalidomide. Among the patients who had received TNF-alpha antagonists, clinical remission was obtained in 47191 patients (51%), while endoscopic remission was observed in 21/46(45%) who had a control colonoscopy. Conclusion. One fifth of our Behcet's syndrome patients with gastrointestinal involvement were refractory to conventional treatment modalities. Remission was obtained with TNF-alpha antagonists and/or thalidomide in about 75 % of the cases.
